FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380084501> ?p ?o ?g. }

• W4380084501 abstract "Osteosarcoma (OS) patients that present with metastatic disease have a poor prognosis and no curative options. Allogeneic bone marrow transplant (alloBMT) is curative for hematologic malignancies through the graft-versus-tumor (GVT) effect, but to date has been ineffective for solid tumors like OS. CD155 is expressed on OS and interacts strongly with the inhibitory receptors TIGIT and CD96 but also binds to the activating receptor DNAM-1 on natural killer (NK) cells but has never been targeted after alloBMT. Combining adoptive transfer of allogeneic NK (alloNK) cells with CD155 checkpoint blockade after alloBMT may enhance a GVT effect against OS but could enhance toxicities like graft-versus-host-disease (GVHD).Ex vivo activated and expanded murine NK cells were generated with soluble IL-15/IL-15Rα. AlloNK and syngeneic NK (synNK) cell phenotype, cytotoxicity, cytokine production, and degranulation against the CD155-expressing murine OS cell line K7M2 were assessed in vitro. Mice bearing pulmonary OS metastases underwent alloBMT followed by infusion of alloNK cells with combinations of anti-CD155 and anti-DNAM-1 blockade. Tumor growth, GVHD and survival were monitored and differential gene expression of lung tissue was assessed by RNA microarray.AlloNK cells exhibited superior cytotoxicity against CD155-expressing OS compared to synNK cells, and this activity was further enhanced by CD155 blockade. CD155 blockade increased alloNK cell degranulation and interferon gamma production through DNAM-1, as these functions were abrogated during DNAM-1 blockade. When alloNKs are given with CD155 blockade after alloBMT, increased survival and decreased burden of relapsed pulmonary OS metastases are observed with no exacerbation of GVHD. In contrast, benefits are not seen if alloBMT is used to treat established pulmonary OS. Treatment with combination CD155 and DNAM-1 blockade decreased survival from OS in vivo, implying DNAM-1 was also necessary for alloNKs in vivo. In mice treated with alloNKs and CD155 blockade, expression of genes related to NK cell cytotoxicity were upregulated. DNAM-1 blockade resulted in upregulation of NK inhibitory receptors and NKG2D ligands on OS, but blockade of NKG2D did not impair cytotoxicity, indicating DNAM-1 is a more potent regulator of alloNK cell anti-OS responses compared to NKG2D.These results demonstrate the safety and efficacy of infusing alloNK cells with CD155 blockade to mount a GVT effect against OS and show benefits are in part through DNAM-1.Allogeneic bone marrow transplant (alloBMT) has yet to show efficacy in treating solid tumors, such as osteosarcoma (OS). CD155 is expressed on OS and interacts with natural killer (NK) cell receptors, such as activating receptor DNAM-1 and inhibitory receptors TIGIT and CD96 and has a dominant inhibitory effect on NK cell activity. Targeting CD155 interactions on allogeneic NK cells could enhance anti-OS responses, but this has not been tested after alloBMT.CD155 blockade enhances allogeneic natural killer cell-mediated cytotoxicity against osteosarcoma and improved overall survival and decreased tumor growth after alloBMT in an in vivo mouse model of metastatic pulmonary OS. Addition of DNAM-1 blockade abrogated CD155 blockade-enhanced allogeneic NK cell antitumor responses.These results demonstrate efficacy of allogeneic NK cells combined with CD155 blockade to mount an antitumor response against CD155-expressing OS. Translation of combination adoptive NK cell and CD155 axis modulation offers a platform for alloBMT treatment approaches for pediatric patients with relapsed and refractory solid tumors." @default.
• W4380084501 created "2023-06-10" @default.
• W4380084501 creator A5008824892 @default.
• W4380084501 creator A5010135236 @default.
• W4380084501 creator A5011569932 @default.
• W4380084501 creator A5019071321 @default.
• W4380084501 creator A5023431998 @default.
• W4380084501 creator A5034324583 @default.
• W4380084501 creator A5036354959 @default.
• W4380084501 creator A5049786167 @default.
• W4380084501 creator A5054397260 @default.
• W4380084501 creator A5063491658 @default.
• W4380084501 creator A5071232709 @default.
• W4380084501 creator A5089532829 @default.
• W4380084501 creator A5089850374 @default.
• W4380084501 creator A5092128894 @default.
• W4380084501 date "2023-06-09" @default.
• W4380084501 modified "2023-09-26" @default.
• W4380084501 title "CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma" @default.
• W4380084501 cites W1544331058 @default.
• W4380084501 cites W1595098530 @default.
• W4380084501 cites W1976229112 @default.
• W4380084501 cites W1981137720 @default.
• W4380084501 cites W1986690159 @default.
• W4380084501 cites W1989712520 @default.
• W4380084501 cites W1993596892 @default.
• W4380084501 cites W2033107431 @default.
• W4380084501 cites W2045097625 @default.
• W4380084501 cites W2057776379 @default.
• W4380084501 cites W2067006752 @default.
• W4380084501 cites W2069773259 @default.
• W4380084501 cites W2073303594 @default.
• W4380084501 cites W2093174360 @default.
• W4380084501 cites W2104192569 @default.
• W4380084501 cites W2121374455 @default.
• W4380084501 cites W2126969366 @default.
• W4380084501 cites W2127748864 @default.
• W4380084501 cites W2134013972 @default.
• W4380084501 cites W2138362010 @default.
• W4380084501 cites W2142256141 @default.
• W4380084501 cites W2142548447 @default.
• W4380084501 cites W2147068163 @default.
• W4380084501 cites W2148801836 @default.
• W4380084501 cites W2149312162 @default.
• W4380084501 cites W2165813814 @default.
• W4380084501 cites W2338392504 @default.
• W4380084501 cites W2516241665 @default.
• W4380084501 cites W2737469573 @default.
• W4380084501 cites W2763653175 @default.
• W4380084501 cites W2942184366 @default.
• W4380084501 cites W3004222930 @default.
• W4380084501 cites W3035082595 @default.
• W4380084501 cites W3037669104 @default.
• W4380084501 cites W3046974375 @default.
• W4380084501 cites W3084404519 @default.
• W4380084501 cites W3104002674 @default.
• W4380084501 cites W3172210430 @default.
• W4380084501 cites W4280543300 @default.
• W4380084501 cites W4303613754 @default.
• W4380084501 cites W4315486681 @default.
• W4380084501 cites W4318475995 @default.
• W4380084501 doi "https://doi.org/10.1101/2023.06.07.544144" @default.
• W4380084501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37333207" @default.
• W4380084501 hasPublicationYear "2023" @default.
• W4380084501 type Work @default.
• W4380084501 citedByCount "0" @default.
• W4380084501 crossrefType "posted-content" @default.
• W4380084501 hasAuthorship W4380084501A5008824892 @default.
• W4380084501 hasAuthorship W4380084501A5010135236 @default.
• W4380084501 hasAuthorship W4380084501A5011569932 @default.
• W4380084501 hasAuthorship W4380084501A5019071321 @default.
• W4380084501 hasAuthorship W4380084501A5023431998 @default.
• W4380084501 hasAuthorship W4380084501A5034324583 @default.
• W4380084501 hasAuthorship W4380084501A5036354959 @default.
• W4380084501 hasAuthorship W4380084501A5049786167 @default.
• W4380084501 hasAuthorship W4380084501A5054397260 @default.
• W4380084501 hasAuthorship W4380084501A5063491658 @default.
• W4380084501 hasAuthorship W4380084501A5071232709 @default.
• W4380084501 hasAuthorship W4380084501A5089532829 @default.
• W4380084501 hasAuthorship W4380084501A5089850374 @default.
• W4380084501 hasAuthorship W4380084501A5092128894 @default.
• W4380084501 hasBestOaLocation W43800845011 @default.
• W4380084501 hasConcept C126322002 @default.
• W4380084501 hasConcept C170493617 @default.
• W4380084501 hasConcept C203014093 @default.
• W4380084501 hasConcept C2776090121 @default.
• W4380084501 hasConcept C2778468042 @default.
• W4380084501 hasConcept C2778690821 @default.
• W4380084501 hasConcept C2779118045 @default.
• W4380084501 hasConcept C2779972918 @default.
• W4380084501 hasConcept C2911091166 @default.
• W4380084501 hasConcept C49802076 @default.
• W4380084501 hasConcept C502942594 @default.
• W4380084501 hasConcept C71924100 @default.
• W4380084501 hasConcept C8891405 @default.
• W4380084501 hasConcept C98274493 @default.
• W4380084501 hasConceptScore W4380084501C126322002 @default.
• W4380084501 hasConceptScore W4380084501C170493617 @default.
• W4380084501 hasConceptScore W4380084501C203014093 @default.
• W4380084501 hasConceptScore W4380084501C2776090121 @default.

• next